- PR Newswire•last monthBioLife Solutions' CryoStor® Embedded in Manufacturing Process for Promethera Biosciences HepaStem Cell-Based Treatment for Liver Disorders
BOTHELL, Wash., Sept. 15, 2016 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage ...
- PR Newswire•2 months agoBioLife Solutions' CryoStor® Integrated in Kolon Group's Cell-Mediated Gene Therapy for Osteoarthritis
BOTHELL, Wash., Aug. 24, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science. According to Kolon, Invossa is the world's first cell-mediated gene therapy for osteoarthritis, a degenerative joint disease affecting more than 150 million people.
BioLife Solutions, Inc. (BLFS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||1.29 x 100|
|Ask||1.80 x 500|
|Day's Range||1.67 - 1.71|
|52wk Range||1.46 - 3.58|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.40|
|Avg Vol (3m)||82,604|
|Dividend & Yield||N/A (N/A)|